{"id":774,"date":"2026-06-26T23:21:31","date_gmt":"2026-06-27T03:21:31","guid":{"rendered":"https:\/\/www.durhampeptides.ca\/post\/cjc-1295-no-dac-vs-dac"},"modified":"2026-09-26T20:03:11","modified_gmt":"2026-09-27T00:03:11","slug":"cjc-1295-no-dac-vs-dac","status":"publish","type":"post","link":"https:\/\/www.durhampeptides.ca\/fr\/post\/cjc-1295-no-dac-vs-dac","title":{"rendered":"CJC-1295 No DAC vs CJC-1295 DAC: Why Durham Peptides Stocks the No DAC Version"},"content":{"rendered":"<figure><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-165\" src=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/cjc-1295-no-dac-10mg.png\" alt=\"CJC-1295 No DAC vs DAC half-life pulsatile sustained GH release research peptide comparison Durham Peptides Canada\" width=\"1122\" height=\"1402\" srcset=\"https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/cjc-1295-no-dac-10mg.png 1122w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/cjc-1295-no-dac-10mg-240x300.webp 240w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/cjc-1295-no-dac-10mg-819x1024.webp 819w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/cjc-1295-no-dac-10mg-768x960.webp 768w, https:\/\/www.durhampeptides.ca\/wp-content\/uploads\/2026\/10\/cjc-1295-no-dac-10mg-800x1000.webp 800w\" sizes=\"(max-width: 1122px) 100vw, 1122px\" \/><\/figure>\n<p>CJC-1295 No DAC vs DAC half-life pulsatile sustained GH release research peptide comparison Durham Peptides Canada<\/p>\n<p><\/p>\n<p>Researchers looking at CJC-1295 quickly encounter a confusing reality: there are actually <strong>two different CJC-1295 compounds<\/strong> \u2014 \"CJC-1295 with DAC\" and \"CJC-1295 without DAC\" (also called \"Mod GRF 1-29\" or simply \"CJC-1295 No DAC\"). They share most of their structure but have one critical difference that produces dramatically different research profiles. Durham Peptides stocks the <strong>No DAC version<\/strong> specifically, and that choice reflects a real research-design preference, not an arbitrary product selection. This article walks through why.<\/p>\n<p><\/p>\n<p>For the broader CJC-1295 context, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/what-is-cjc-1295\/\" target=\"_blank\">What Is CJC-1295?<\/a><\/u>; for the combination with Ipamorelin, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/cjc-1295-vs-ipamorelin\/\" target=\"_blank\">CJC-1295 vs Ipamorelin<\/a><\/u>; for the broader GHRH analog comparison, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/tesamorelin-vs-cjc-1295-vs-sermorelin\/\" target=\"_blank\">Tesamorelin vs CJC-1295 vs Sermorelin<\/a><\/u>. Nothing here is medical, dosing, or therapeutic guidance.<\/p>\n<p><\/p>\n<p><strong>Both Versions Share the Same Core<\/strong><\/p>\n<p><\/p>\n<p>Before getting to the difference, the similarity. Both CJC-1295 variants share:<\/p>\n<ul><li><strong>The same modified GHRH(1-29) sequence.<\/strong> GHRH (growth hormone releasing hormone) is naturally 44 amino acids; the first 29 amino acids carry most of the biological activity. CJC-1295 is built on this GHRH(1-29) backbone with four amino acid substitutions designed to resist degradation.<\/li><li><strong>The same target receptor.<\/strong> Both versions bind the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and release through the GHRH pathway.<\/li><li><strong>The same fundamental research category.<\/strong> Both are GHRH analogs studied in growth hormone research.<\/li><\/ul>\n<p><\/p>\n<p>So the foundational mechanism is identical. What differs is one specific structural feature that has dramatic functional consequences.<\/p>\n<p><\/p>\n<p><strong>The DAC Difference: A Single Molecule, Massively Different Behavior<\/strong><\/p>\n<p><\/p>\n<p><strong>DAC<\/strong> stands for <strong>Drug Affinity Complex<\/strong>. It's a chemical modification \u2014 specifically, a maleimidopropionic acid linker \u2014 added to the CJC-1295 backbone. The DAC linker covalently binds to albumin (the most abundant blood protein) when CJC-1295 enters circulation, anchoring the peptide to albumin's multi-day circulation lifetime.<\/p>\n<p><\/p>\n<p><strong>The functional consequence:<\/strong> Albumin has a half-life of roughly 19-20 days. By covalently binding to albumin, CJC-1295 DAC extends its functional half-life from minutes (the natural fate of unmodified peptides) to approximately <strong>6-8 days<\/strong>. CJC-1295 No DAC, without the albumin-binding linker, has a half-life closer to <strong>30 minutes<\/strong>.<\/p>\n<p><\/p>\n<p>So the same core peptide, with or without a single chemical modification, has half-lives that differ by <strong>roughly 300x<\/strong> \u2014 minutes versus days. This is a remarkable functional difference for what looks like a small structural change.<\/p>\n<p><\/p>\n<p><strong>Side-by-Side<\/strong><\/p>\n<table><tr><td><p>Property<\/p><\/td><td><p>CJC-1295 No DAC<\/p><\/td><td><p>CJC-1295 DAC<\/p><\/td><\/tr><tr><td><p>Core sequence<\/p><\/td><td><p>Modified GHRH(1-29)<\/p><\/td><td><p>Modified GHRH(1-29)<\/p><\/td><\/tr><tr><td><p>DAC linker<\/p><\/td><td><p>None<\/p><\/td><td><p>Maleimidopropionic acid linker<\/p><\/td><\/tr><tr><td><p>Albumin binding<\/p><\/td><td><p>No<\/p><\/td><td><p>Yes (covalent)<\/p><\/td><\/tr><tr><td><p>Half-life<\/p><\/td><td><p>~30 minutes<\/p><\/td><td><p>~6-8 days<\/p><\/td><\/tr><tr><td><p>GH release profile<\/p><\/td><td><p>Pulsatile (rises, peaks, clears)<\/p><\/td><td><p>Sustained (continuous elevation)<\/p><\/td><\/tr><tr><td><p>Research alignment<\/p><\/td><td><p>Mimics physiological GH pulsing<\/p><\/td><td><p>Continuous-elevation research model<\/p><\/td><\/tr><tr><td><p>Common research pairing<\/p><\/td><td><p>Ipamorelin (also pulsatile, also short half-life)<\/p><\/td><td><p>Less commonly paired with short-half-life compounds<\/p><\/td><\/tr><tr><td><p>Durham Peptides<\/p><\/td><td><p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-no-dac-10mg\/\" target=\"_blank\">CJC-1295 No DAC 10mg<\/a><\/u> ($69.99)<\/p><\/td><td><p>Not stocked<\/p><\/td><\/tr><tr><td><p>Also called<\/p><\/td><td><p>Mod GRF 1-29; CJC-1295 No-DAC<\/p><\/td><td><p>CJC-1295 with DAC; CJC-1295 (DAC)<\/p><\/td><\/tr><\/table>\n<p><strong>Why Pulsatile vs Sustained Matters in GH Research<\/strong><\/p>\n<p><\/p>\n<p>To understand why the half-life difference is a research-design distinction (not just a duration preference), you have to understand how the body naturally secretes GH.<\/p>\n<p><\/p>\n<p><strong>Endogenous GH is pulsatile.<\/strong> Growth hormone is not secreted continuously. Instead, the pituitary releases GH in <strong>discrete pulses<\/strong> \u2014 typically several per day, with the largest pulses occurring during deep sleep. Between pulses, GH levels return to low baseline. This pulsatile pattern is biologically important: research has shown that <strong>the same total amount of GH delivered as pulses produces different biological effects than the same total delivered as continuous infusion.<\/strong>Receptor desensitization, downstream signaling kinetics, and the timing of IGF-1 production all behave differently under pulsatile vs sustained GH exposure.<\/p>\n<p><\/p>\n<p><strong>Implication for CJC-1295 research:<\/strong><\/p>\n<ul><li><strong>CJC-1295 No DAC<\/strong> (short half-life, ~30 minutes) produces a discrete GH pulse each time it's administered \u2014 rising quickly, peaking, and clearing. This mimics the body's natural pulsatile GH pattern. For research designed around physiological GH-release dynamics, this is the more research-aligned profile.<\/li><li><strong>CJC-1295 DAC<\/strong> (long half-life, ~6-8 days) produces a sustained continuous elevation in GH levels \u2014 fundamentally different from the body's natural pattern. This may be acceptable for some research questions but represents a non-physiological GH pattern.<\/li><\/ul>\n<p><\/p>\n<p>For most growth hormone research designed around physiologically-relevant patterns, the No DAC version is the more appropriate research tool.<\/p>\n<p><\/p>\n<p><strong>Why Pulsatile Pairs Well with Ipamorelin<\/strong><\/p>\n<p><\/p>\n<p>This is the deeper research-design reason Durham Peptides' catalog stocks CJC-1295 No DAC. <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/ipamorelin-10mg\/\" target=\"_blank\">Ipamorelin<\/a><\/u> \u2014 the selective ghrelin-receptor agonist that's the natural pairing for a GHRH analog \u2014 has its own short half-life (~2 hours) and produces its own pulsatile GH effects. For the receptor and selectivity context, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/ipamorelin-selectivity-explained\/\" target=\"_blank\">Ipamorelin's Selectivity<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>The combination logic:<\/strong><\/p>\n<ul><li><strong>CJC-1295 No DAC + Ipamorelin<\/strong> \u2192 both compounds pulsatile, both clear within hours, combination produces a discrete dual-pathway GH pulse with a clean rise-peak-clear pattern that aligns with physiological GH-release research designs.<\/li><li><strong>CJC-1295 DAC + Ipamorelin<\/strong> \u2192 mismatched kinetics. CJC-1295 DAC produces continuous GHRH-pathway signaling for days while Ipamorelin pulses through over hours. The combination delivers sustained GHRH stimulation overlapping with brief ghrelin-receptor pulses \u2014 a research-design awkwardness that complicates interpretation.<\/li><\/ul>\n<p><\/p>\n<p>For the dual-pathway combination research, the No DAC version of CJC-1295 is mechanistically the better-paired option. This is the rationale behind the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-ipamorelin-blend-10mg\/\" target=\"_blank\">CJC-1295 (No DAC) + Ipamorelin Blend<\/a><\/u> \u2014 both components pulsatile, both short half-life, kinetically matched.<\/p>\n<p><\/p>\n<p>For the combination logic, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/cjc-1295-ipamorelin-blend-explained\/\" target=\"_blank\">CJC-1295 + Ipamorelin Blend Explained<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Why Some Researchers Would Choose the DAC Version<\/strong><\/p>\n<p><\/p>\n<p>To be fair to the DAC version: there are research designs where the sustained-elevation profile is the appropriate tool, not the limitation. Examples:<\/p>\n<ul><li><strong>Research designed specifically around chronically elevated GH<\/strong> (e.g., modeling certain hypersecretion conditions)<\/li><li><strong>Convenience-focused research<\/strong> where weekly administration is preferable to more frequent administration (acknowledging the non-physiological pattern)<\/li><li><strong>IGF-1 elevation research<\/strong> where sustained GH stimulation is the explicit design<\/li><\/ul>\n<p><\/p>\n<p>For most general GH research \u2014 and especially research designed around mimicking endogenous physiological patterns \u2014 the No DAC version's pulsatile profile is the more appropriate match.<\/p>\n<p><\/p>\n<p><strong>Tesamorelin: A Third Option in the Same Receptor Family<\/strong><\/p>\n<p><\/p>\n<p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/tesamorelin\/\" target=\"_blank\">Tesamorelin<\/a><\/u> is the other major GHRH analog in research and uses a different stabilization strategy \u2014 a trans-3-hexenoic acid N-terminal modification rather than amino acid substitutions or DAC linkers. Tesamorelin's half-life sits between the two CJC-1295 versions and produces a different research-kinetic profile. For the head-to-head, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/tesamorelin-vs-cjc-1295-vs-sermorelin\/\" target=\"_blank\">Tesamorelin vs CJC-1295 vs Sermorelin<\/a><\/u>; for the broader GHRH-vs-GHS comparison, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/tesamorelin-vs-ipamorelin\/\" target=\"_blank\">Tesamorelin vs Ipamorelin<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Practical Research Considerations<\/strong><\/p>\n<p><\/p>\n<p><u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-no-dac-10mg\/\" target=\"_blank\">CJC-1295 (No DAC) 10mg<\/a><\/u> at Durham Peptides is C$69.99 (C$7.00\/mg), Janoshik-verified to \u226599% purity by HPLC with mass-spec identity confirmation; 100% synthetic; vegan. Storage: 2\u20138\u00b0C short-term, -20\u00b0C long-term, protected from light and moisture; reconstitute in <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/bacteriostatic-water-10ml\/\" target=\"_blank\">eau bact\u00e9riostatique<\/a><\/u>. The <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-ipamorelin-blend-10mg\/\" target=\"_blank\">CJC-1295 + Ipamorelin Blend<\/a><\/u> at C$94.99 provides the standard combination format for dual-pathway GH research.<\/p>\n<p><\/p>\n<p><strong>Questions fr\u00e9quentes<\/strong><\/p>\n<p><\/p>\n<p><strong>What's the difference between CJC-1295 No DAC and CJC-1295 DAC?<\/strong> The DAC version has a Drug Affinity Complex linker that covalently binds albumin, extending half-life from ~30 minutes (No DAC) to ~6-8 days (DAC). Same core peptide, dramatically different kinetics.<\/p>\n<p><\/p>\n<p><strong>Why does Durham Peptides stock the No DAC version specifically?<\/strong> Because the No DAC version's short half-life produces a pulsatile GH release pattern that mimics the body's natural GH secretion. This aligns better with research designed around physiological GH dynamics \u2014 and it kinetically matches Ipamorelin for combination research.<\/p>\n<p><\/p>\n<p><strong>Is CJC-1295 No DAC the same as Mod GRF 1-29?<\/strong> Yes \u2014 they're alternate names for the same compound. The modified GHRH(1-29) backbone without the DAC albumin-binding linker.<\/p>\n<p><\/p>\n<p><strong>Does the half-life difference change the GH effect?<\/strong> Yes, substantially. The same amount of GH delivered as a pulse produces different biological effects than the same amount delivered as continuous elevation \u2014 receptor desensitization, downstream signaling kinetics, and IGF-1 timing all differ.<\/p>\n<p><\/p>\n<p><strong>Can the two versions be combined with Ipamorelin?<\/strong> The No DAC version pairs naturally with Ipamorelin (both pulsatile, both short half-life, kinetically matched). The DAC version's sustained profile mismatches with Ipamorelin's pulsatile profile and produces interpretively complicated combinations.<\/p>\n<p><\/p>\n<p><strong>Where can I buy CJC-1295 No DAC in Canada?<\/strong> Durham Peptides supplies <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-no-dac-10mg\/\" target=\"_blank\">CJC-1295 (No DAC) 10mg<\/a><\/u> (C$69.99) standalone and in the <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/cjc-1295-ipamorelin-blend-10mg\/\" target=\"_blank\">CJC-1295 + Ipamorelin Blend<\/a><\/u> (C$94.99), both Janoshik-verified.<\/p>\n<p><\/p>\n<p><strong>Final Thoughts<\/strong><\/p>\n<p><\/p>\n<p>The CJC-1295 No DAC vs DAC distinction is one of the cleanest examples of how a small structural modification \u2014 a single linker added to a peptide backbone \u2014 can produce dramatically different research profiles. The DAC linker extends half-life by roughly 300x by covalently binding albumin, transforming a pulsatile research tool into a sustained-elevation research tool. For most GH research designed around physiologically-relevant patterns, the No DAC version is the better-matched tool \u2014 which is why Durham Peptides stocks the No DAC version specifically and pairs it with Ipamorelin in the combination blend.<\/p>\n<p><\/p>\n<p>For the broader CJC-1295 context, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/what-is-cjc-1295\/\" target=\"_blank\">What Is CJC-1295?<\/a><\/u>; for the combination logic, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/cjc-1295-ipamorelin-blend-explained\/\" target=\"_blank\">CJC-1295 + Ipamorelin Blend Explained<\/a><\/u>; for the receptor and selectivity context on the Ipamorelin side of the pairing, see <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/post\/ipamorelin-selectivity-explained\/\" target=\"_blank\">Ipamorelin's Selectivity<\/a><\/u>.<\/p>\n<p><\/p>\n<p><strong>Selected Research References<\/strong><\/p>\n<p><\/p>\n<ol><li>Teichman SL, Neale A, Lawrence B, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone. <em>Journal of Clinical Endocrinology &amp; Metabolism<\/em>. 2006;91(3):799-805. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/<\/a><\/u><\/li><li>Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH\/IGF-1 Axis by CJC-1295, a Long-Acting GHRH Analog. <em>Endocrine<\/em>. 2009. (Foundational reference on CJC-1295 mechanism characterization.)<\/li><li>Bowers CY. Editorial: Unnatural Growth Hormone-Releasing Peptide Begets Natural Ghrelin. <em>Journal of Clinical Endocrinology &amp; Metabolism<\/em>. 2001;86(4):1464-1469. <u><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/11297567\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/11297567\/<\/a><\/u><\/li><li>M\u00fcller EE, Locatelli V, Cocchi D. Neuroendocrine Control of Growth Hormone Secretion. <em>Physiological Reviews<\/em>. 1999;79(2):511-607. (Reference on pulsatile vs sustained GH pattern biology.)<\/li><\/ol>\n<p><\/p>\n<p><em>All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.<\/em><\/p>","protected":false},"excerpt":{"rendered":"CJC-1295 No DAC vs DAC half-life pulsatile sustained GH release research peptide comparison Durham Peptides Canada Researchers looking at CJC-1295 quickly encounter a confusing reality: there are actually two different CJC-1295 compounds \u2014 \"CJC-1295 with DAC\" and \"CJC-1295 without DAC\" (also called \"Mod GRF 1-29\" or simply \"CJC-1295 No DAC\"). They share most of their structure but have one critical difference that produces dramatically different research profiles. Durham Peptides stocks the...","protected":false},"author":1,"featured_media":165,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-774","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-science"],"_links":{"self":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/comments?post=774"}],"version-history":[{"count":1,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/774\/revisions"}],"predecessor-version":[{"id":1115,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/774\/revisions\/1115"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media\/165"}],"wp:attachment":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media?parent=774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/categories?post=774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/tags?post=774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}